These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33476309)

  • 1. [Fabry disease in cardiology: Diagnosis and therapeutic approaches].
    Çavuşoğlu Y; Özpelit E; Arslan N; Demir M; Kahveci G; Onay H; Ökçün EÖB; Tufekcioglu O; Tülüce SY; Yıldırım GK
    Turk Kardiyol Dern Ars; 2020 Dec; 48(Suppl 2):1-42. PubMed ID: 33476309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabry disease.
    Yuasa T; Takenaka T; Higuchi K; Uchiyama N; Horizoe Y; Cyaen H; Mizukami N; Takasaki K; Kisanuki A; Miyata M; Ohishi M
    J Echocardiogr; 2017 Dec; 15(4):151-157. PubMed ID: 28674962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fabry disease in cardiology practice: Literature review and expert point of view.
    Hagège A; Réant P; Habib G; Damy T; Barone-Rochette G; Soulat G; Donal E; Germain DP
    Arch Cardiovasc Dis; 2019 Apr; 112(4):278-287. PubMed ID: 30826269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
    Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
    Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease: treatment and diagnosis.
    Rozenfeld PA
    IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The heart in Anderson Fabry disease.
    Kampmann C; Wiethoff CM; Perrot A; Beck M; Dietz R; Osterziel KJ
    Z Kardiol; 2002 Oct; 91(10):786-95. PubMed ID: 12395219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The neurological manifestations of Fabry disease. A review].
    Firsov KV; Kotov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(9):98-105. PubMed ID: 27735906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anderson-Fabry disease and the heart.
    O'Mahony C; Elliott P
    Prog Cardiovasc Dis; 2010; 52(4):326-35. PubMed ID: 20109602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabry disease.
    Germain DP
    Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
    Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
    Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.
    Putko BN; Wen K; Thompson RB; Mullen J; Shanks M; Yogasundaram H; Sergi C; Oudit GY
    Heart Fail Rev; 2015 Mar; 20(2):179-91. PubMed ID: 25030479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fabry cardiomyopathy: models for the cardiologist.
    Weidemann F; Niemann M; Warnock DG; Ertl G; Wanner C
    Annu Rev Med; 2011; 62():59-67. PubMed ID: 21090963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.
    Chimenti C; Pieroni M; Morgante E; Antuzzi D; Russo A; Russo MA; Maseri A; Frustaci A
    Circulation; 2004 Aug; 110(9):1047-53. PubMed ID: 15313943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.
    Maron MS; Xin W; Sims KB; Butler R; Haas TS; Rowin EJ; Desnick RJ; Maron BJ
    Am J Med; 2018 Feb; 131(2):200.e1-200.e8. PubMed ID: 28943383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fabry disease.
    Tarabuso AL
    Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive clinical evaluation of a large Spanish family with Anderson-Fabry disease, novel GLA mutation and severe cardiac phenotype.
    San Román-Monserrat I; Moreno-Flores V; López-Cuenca D; Rodríguez-González-Herrero E; Guillén-Navarro E; Rodríguez-González-Herrero B; Alegría-Fernández M; Poza-Cisneros G; Piñero-Fernández JA; Sornichero-Martínez J; Gimeno-Blanes JR
    Med Clin (Barc); 2014 Jun; 142(11):497-504. PubMed ID: 24679964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular hypertrophy: do not forget Fabry disease. Diagnostic work-up and differential diagnosis.
    Paelinck BP; Bondue A; Robyns T; Eyskens F
    Acta Cardiol; 2024 Aug; 79(6):642-649. PubMed ID: 38869089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.